Latest News and Press Releases

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...

NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...

COMMUNIQUE DE PRESSE UN ARTICLE DE LA REVUE DE REFERENCE LIFE SCIENCES MAGAZINE PRÉSENTE LE MASITINIB D'AB SCIENCE ET SON INVESTIGATEUR PRINCIPAL DE PHASE 3, LE NEUROLOGUE PATRICK VERMERSCH Paris, 4...

PRESS RELEASE ARTICLE FROM THE LEADING PUBLICATION LIFE SCIENCES MAGAZINE FEATURING AB SCIENCE’S MASITINIB AND ITS PHASE 3 PRINCIPAL INVESTIGATOR, THE NEUROLOGIST PATRICK VERMERSCH Paris, March 04,...

Phase 1 Data at ACTRIMS Forum 2025 supports potential of A-005 as first-in-class CNS-penetrant TYK2 Inhibitor for neuroinflammatory diseases

SAN FRANCISCO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Researchers at New York University (NYU) found that a particular set of brain exercises lowered the incidence of the all-too-common symptom of...

Pune, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Multiple Sclerosis Market Size & Growth Analysis: “According to SNS Insider, The Multiple Sclerosis Market size is projected to grow from USD 23.64...

NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...